Publications by authors named "J S Rech"
Introduction: Interim analysis of the long-term safety and effectiveness of canakinumab, at a patient level, in the mevalonate kinase deficiency/hyperimmunoglobulin-D syndrome (MKD/HIDS) cohort of the RELIANCE registry.
Methods: From June 2018, the RELIANCE registry enrolled paediatric (aged ≥ 2 years) and adult patients (aged ≥ 18 years) with MKD/HIDS who were receiving canakinumab as part of their routine medical care. Safety, physician- and patient-reported measures of disease activity and dosing patterns were evaluated at baseline and every 6 months until end-of-study visit.
Background: Adult-onset Still's disease (AOSD) is a rare autoinflammatory disease. Since it can lead to variable organ involvement, including life-threatening complications, and due to newly available therapeutic approaches, the German Society for Rheumatology and Clinical Immunology (Deutsche Gesellschaft für Rheumatologie und klinische Immunologie; DGRh) issued a newly developed S2e guideline in December 2022.
Objective: This study aims to investigate the influence of the new guideline on the diagnosis, management, and outcomes of AOSD.
Positive allosteric modulation of the mu-opioid receptor is a promising strategy to address the ever-growing problem of acute and chronic pain management. Positive allosteric modulators (PAMs) of the mu-opioid receptor could be employed to enhance the efficacy of endogenous opioid peptides to a degree that provides pain relief without the need for traditional opioid drugs. Alternatively, PAMs might be used to enhance the action of opioid drugs and so provide an opioid-sparing effect, allowing for the use of lower doses of opioid agonists and potentially decreasing associated side effects.
View Article and Find Full Text PDFArticle Synopsis
- * The ST2/IL-33 pathway promotes immune tolerance by expanding regulatory T cells but also triggers proinflammatory cytokine production for immune defense and tissue repair.
- * Researchers developed improved ST2 inhibitors that effectively reduced ST2 upregulation and IL-1β release in human mast cells, suggesting potential for treating diseases mediated by mast cells.
Article Synopsis
- Adult-onset Still's disease (AOSD) is a complex autoinflammatory disorder with unclear causes, and this study aims to explore its genetic background and potential treatment targets.
- Researchers analyzed 60 AOSD patients using advanced genetic techniques and blood profiling to uncover rare genetic variants and inflammation markers.
- Results indicated a higher frequency of certain genetic variants and significant elevation of specific cytokines and immune system markers in AOSD patients, suggesting a complicated genetic landscape that could lead to new approaches in treatment.